Total submissions: 12
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000232551 | SCV000289497 | benign | not provided | 2025-02-03 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000232551 | SCV000518908 | benign | not provided | 2019-03-01 | criteria provided, single submitter | clinical testing | |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV000232551 | SCV000602101 | benign | not provided | 2023-06-20 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000570065 | SCV000671273 | benign | Hereditary cancer-predisposing syndrome | 2015-08-22 | criteria provided, single submitter | clinical testing | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Prevention |
RCV000423707 | SCV000806857 | benign | not specified | 2018-01-10 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000423707 | SCV000920071 | benign | not specified | 2018-01-08 | criteria provided, single submitter | clinical testing | Variant summary: The POLE c.846C>T (p.Pro282Pro) variant involves the alteration of a non-conserved nucleotide located in the DNA-directed DNA polymerase, family B, exonuclease domain (IPR006133) (InterPro), resulting in a synonymous change. One in silico tool predicts a damaging outcome for this variant. This variant was found in 282/277164 control chromosomes (2 homozygotes) in gnomAD at a frequency of 0.0010174, which is approximately 72 times the estimated maximal expected allele frequency of a pathogenic POLE variant (0.0000142), suggesting this variant is likely a benign polymorphism. In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as likely benign/benign. The variant of interest has not, to our knowledge, been reported in affected individuals via publications and/or reputable databases/clinical diagnostic laboratories; nor evaluated for functional impact by in vivo/vitro studies. Taken together, this variant is classified as benign. |
Genetic Services Laboratory, |
RCV000423707 | SCV002071594 | benign | not specified | 2018-05-23 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002503914 | SCV002811230 | likely benign | Colorectal cancer, susceptibility to, 12; Facial dysmorphism-immunodeficiency-livedo-short stature syndrome; Intrauterine growth retardation, metaphyseal dysplasia, adrenal hypoplasia congenita, genital anomalies, and immunodeficiency | 2021-07-14 | criteria provided, single submitter | clinical testing | |
KCCC/NGS Laboratory, |
RCV001079650 | SCV004017090 | benign | Colorectal cancer, susceptibility to, 12 | 2023-07-07 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000232551 | SCV005435810 | likely benign | not provided | 2024-11-01 | criteria provided, single submitter | clinical testing | POLE: BP4, BP7, BS1 |
Institute for Biomarker Research, |
RCV000570065 | SCV005688849 | benign | Hereditary cancer-predisposing syndrome | 2025-01-27 | criteria provided, single submitter | clinical testing | The synonymous variant NM_006231.4(POLE):c.846C>T (p.Pro282=) has been reported to ClinVar as Benign/Likely benign with a status of (2 stars) criteria provided, multiple submitters, no conflicts (Variation ID 240632 as of 2025-01-02). . The p.Pro282= variant is observed in 18/5,008 (0.3594%) alleles from individuals of 1kG All background in 1kG, which is greater than expected for the disorder. The p.Pro282= variant is not predicted to disrupt an existing splice site. The p.Pro282= variant results in a substitution of a base that is not predicted conserved by GERP++ and PhyloP. For these reasons, this variant has been classified as Benign. |
True Health Diagnostics | RCV000570065 | SCV000886717 | likely benign | Hereditary cancer-predisposing syndrome | 2018-10-04 | no assertion criteria provided | clinical testing |